If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

GABAA/Bz Receptor Subtypes as Targets for Selective Drugs

$63.10 plus tax (Refund Policy)

Buy Article:

Abstract:

The γ-aminobutyric acid type A (GABAA) receptors are the major inhibitory neuronal receptors in the mammalian brain. Their activation by GABA opens the intrinsic ion channel, enabling chloride flux into the cell with subsequent hyperpolarization. Several GABAA receptor subunit isoforms have been cloned, the major isoform containing α, β, and γ subunits, and a regional heterogeneity associated with distinct physiological effects has been suggested. As a variety of allosteric ligands can modulate GABA-gated conductance changes through binding to distinct sites, the development of subtype-selective ligands may lead to the selective treatment of GABA system- associated pathology. In particular, the best characterized binding site is the benzodiazepine site (BzR), localized at the α/γ subunit interface, in which the α subunit is the main determinant of BzR ligand action selectivity. The α1-containing BzR have been proposed to be responsible for the sedative action; the α2 and/or the α3 subtypes have been suggested to mediate the anxiolytic activity and the myorelaxation effects, and the α5 subtype has been associated with cognition processes. The discovery of α-selective subtype ligands may help in the specific treatment of anxiety, sleep disorders, convulsions and memory deficits with fewer side effects. Selectivity may be achieved by two approaches: selective affinity or selective efficacy. Selective affinity needs a compound to bind with a higher affinity to one receptor subtype compared with another, whereas subtype-selective efficacy relies on a compound binding to all subtypes, but having different efficacies at various subtypes. The status of BzR ligands, subdivided on the basis of their main chemical structural features, is reviewed in relation to structure-activity relationships which determine their affinity or efficacy selectivity for a certain BzR subtype.

Keywords: BzR ligands; GABAA/BzR complex; affinity-selectivity; efficacy-selectivity; structure-activity relationships; α-BzR isoforms

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986707782023190

Affiliations: Dipartimento di Psichiatria, Neurobiologia,Farmacologia e Biotecnologie, Universita di Pisa, Via Bonanno 6, 56126 Pisa,Italy.

Publication date: October 1, 2007

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more